Article, News
Prescient Therapeutics: cashed up with encouraging results flowing
Prescient Therapeutics (ASX: PTX) reported encouraging results in several key targeted and cell therapies in its September quarter activities report. The clinical-stage oncology company report…
Article, News
Quarterly wrap: Sunshine hits QLD copper, Tempus targets Canadian gold and Basin drills Alaskan uranium
It’s a wrap for the September quarter. Here are some of the latest highlights from a few ASX small and midcaps on their activities for…
Article, News
Prescient to unveil trial results at prestigious ASH conference
Prescient Therapeutics (ASX: PTX) has been invited to present clinical data at the prestigious American Society of Hematology (ASH) Annual Meeting in December.
Article, News
Prescient prepares to unveil Phase 1b cancer trial findings at world’s largest haematology conference
Clinical stage oncology company Prescient Therapeutics will showcase the results of its Phase 1b study in relapsed and refractory T cell lymphomas (TCL) at the largest…
Article, News
Prescient Therapeutics to present latest cancer treatment breakthroughs at world-leading conference
Australian clinical stage oncology company Prescient Therapeutics (ASX: PTX) is set to present the exciting results from its latest cancer treatment study at the world’s largest hematology…
Article, News
Prescient Therapeutics (ASX: PTX) to present Phase 1b cancer trial data at prestigious haematology conference
Prescient Therapeutics (ASX: PTX) to present Phase 1b cancer trial data at prestigious haematology conference
Article, News
Prescient to announce Phase 1b cancer trial results at world’s largest haematology conference
Prescient Therapeutics (ASX:PTX) has announced that its abstract for the results of a Phase 1b study in T-cell lymphomas has been accepted for poster presentation…
Article, News
Prescient Therapeutics to present clinical data at prestigious US conference
Results of a Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) Phase 1b study in T cell lymphomas have been accepted for poster presentation at the prestigious American Society of Hematology…
Article, News
Why are clinical advances by this small-cap ASX biotech in FY23 so significant?
Prescient Therapeutics Limited (ASX: PTX) has been witnessing significant achievements and progress towards its goal of developing targeted cancer treatments. In the latest financial year…
Article, News
Prescient Therapeutics prepares for ‘pivotal’ year of PTX-100 development to treat T-cell lymphomas
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has reported a solid end to financial year 2023 which it says has set the stage for a pivotal…